Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
about
Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical ProblemThe evolution of selective estrogen receptor modulators in osteoporosis therapyTailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.What Matters to Women When Making Decisions About Breast Cancer Chemoprevention?Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect RatioOsteoporosis-related fracture case definitions for population-based administrative data.Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study.Fracture risk in women with breast cancer: a population-based study.Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β.Fracture risk in older, long-term survivors of early-stage breast cancer.A review of the use of exemestane in early breast cancer.Aging and osteoporosis in breast and prostate cancer.Adverse skeletal effects of drugs - beyond Glucocorticoids.Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.Cause-specific mortality in women with breast cancer in situ.Elevated incidence of fractures in women with invasive breast cancer.Performance of comorbidity measures for predicting outcomes in population-based osteoporosis cohorts.Lumbar Scoliosis in Patients With Breast Cancer: Prevalence and Relationship With Breast Cancer Treatment, Age, Bone Mineral Density, and Body Mass Index.The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study.Bone Protective Effects of Danggui Buxue Tang Alone and in Combination With Tamoxifen or Raloxifene and
P2860
Q26782584-AF6B73F9-7FC5-4AE9-BCA8-4E1A3C5C4CDBQ26827973-20C38172-5954-4B2E-88CE-B8F0A7C8D0A4Q33781027-B7E1298A-CE38-431D-836A-AA0146D970CEQ33910927-977E94A0-2335-4175-B7B4-4EBA49349EBFQ34095816-C3F48845-94BB-4ED7-A20F-4627B648D015Q34248274-A33BCD21-8946-4E3A-AB0B-804FD9F518D1Q35627029-974DEA1B-B238-4BD9-BC72-EE8B53D824D0Q35991921-0CC7C9CE-02B5-4181-8B26-65E80A875C30Q36724963-3FBAC5AE-8C33-466A-9A3A-239BF3C94793Q36941189-FFA7656F-288C-42C6-BCFA-99B81FAFD8F0Q37230265-3033ED82-4A8B-4D2B-B247-8066569F64D2Q37872146-9142C3FC-B533-4FDA-BA10-38B9FD94CCABQ38231316-A48720C1-20C3-4F5E-838C-5A9FDC803F07Q38553766-BEF55858-6222-4B4C-90EF-F66851EC71B5Q40554954-DF307F43-18E9-4CB0-9B95-7A3791BA2BC5Q40595247-8969999B-A1F1-4B34-805B-D044A6936699Q41464715-90DAB2D4-45CE-44F4-8923-806465231ED3Q44366109-ED74FCF1-7070-4BA1-8DC0-E45235AD2587Q46735572-064244CB-B287-4EFC-AFE6-2C779325462DQ47424252-2EC51D61-8123-4108-98F7-B6C1BA23E098Q58785773-25A21321-AAFE-4B49-8439-819335B55E6B
P2860
Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
@en
Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
@nl
type
label
Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
@en
Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
@nl
prefLabel
Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
@en
Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
@nl
P2093
P356
P1476
Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
@en
P2093
Andrew L Cooke
Colleen Metge
Heather J Prior
P304
P356
10.1200/JCO.2007.15.7123
P407
P577
2008-10-06T00:00:00Z